Abstract 3619
Background
The response to ICI in cervical cancer remains modest and predictive biomarkers to select patients (pts) are needed. An IPI score combining lactate dehydrogenase (LDH) level and the derived neutrophils/ (leucocytes minus neutrophils) ratio (dNLR) has been shown to correlate with ICI outcome in melanoma and lung cancer. We aimed to assess the predictive value of baseline IPI for advanced cervical cancer treated with ICI.
Methods
Pre-ICI treatment dNLR and LDH were retrospectively collected for all pts with advanced cervical cancer treated at our institution with PD1/PDL1 inhibitors (n = 48). Patients were divided into three groups: IPI-0 (normal LDH, dNLR<3), IPI-1 (LDH>upper limit or dNLR>3), and IPI-2 (LDH>upper limit and dNLR>3). The primary endpoint was overall survival (OS) and the secondary objective was progression free survival analyzed by Kaplan Meyer and log-rank (PFS).
Results
In our cohort of 48 pts, 37 (77%) had squamous histology, median age was 47 (range 21 to 76), and 46 (95%) had performance status of 0 or 1. Among the 14 pts with papilloma virus (HPV) testing, 100% were HPV+. PDL1 expression >1% was detected in 9 of 13 patients tested (69%). Most patients were previously treated with at least one line of previous systemic therapy (92%). The majority were treated in phase 1 trials (n = 37) and 25 received ICI in combination with antiangiogenic therapy or another ICI. 22 patients were IPI-0, 22 IPI-1, and 4 IPI-2. Median OS and PFS for our cohort were 14.7 and 3.4 months, respectively. Median PFS in the three groups was 4.9 months, 2.6 months and 0.6 months, respectively (p = 0.004). Median OS was 19.3, 10.4, and 0.9 for IPI 0, 1, and 2, respectively (p = 0.003). OS was 8.9 months for patients who received ICI as monotherapy, whereas OS for the combination group had not yet been reached.
Conclusions
Baseline IPI was highly correlated with ICI-treated cervical cancer pt outcomes. Pts with higher IPI had poorer survival and are likely worse candidates for ICI, particularly as monotherapy. IPI score should be considered in addition to PDL1 status before introducing ICI in patients with advanced cervical cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
F. Blanc-Durand: Speaker Bureau / Expert testimony: Janssen Cylag; Travel / Accommodation / Expenses: Pfizer. P. Pautier: Travel / Accommodation / Expenses, Officer / Board of Directors: AstraZeneca; Travel / Accommodation / Expenses, Officer / Board of Directors: Roche; Travel / Accommodation / Expenses, Officer / Board of Directors: Tesaro; Officer / Board of Directors: MSD; Officer / Board of Directors: Clovis. C. Massard: Advisory / Consultancy: Amgen; Advisory / Consultancy: Astellas; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy: Beigene; Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy: Celgene; Advisory / Consultancy: Debiopharm; Advisory / Consultancy: Genentech; Advisory / Consultancy: Ipsen; Advisory / Consultancy, Research grant / Funding (institution): Janssen; Advisory / Consultancy, Research grant / Funding (institution): Lilly; Advisory / Consultancy, Research grant / Funding (institution): Medimmune; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Advisory / Consultancy: Orion; Research grant / Funding (institution): Boehringer; Research grant / Funding (institution): Merck. A. Leary: Advisory / Consultancy, Travel / Accommodation / Expenses, PI: Tesaro; Advisory / Consultancy, Travel / Accommodation / Expenses, PI: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses, PI: Clovis; Advisory / Consultancy, PI: Gammamabs; Advisory / Consultancy, Pi: Grindstone; Advisory / Consultancy, Pi: Seattle Genetics; Advisory / Consultancy, PI: Pfizer; Advisory / Consultancy, PI: MSD; Advisory / Consultancy, PI: BMS. All other authors have declared no conflicts of interest.
Resources from the same session
3902 - The efficacy of preoperative breast cancer chemotherapy without anti-HER2-targeted treatment – single center experience in setting of no reimbursement in Poland (2011-2015)
Presenter: Agnieszka Badora-Rybicka
Session: Poster Display session 2
Resources:
Abstract
4733 - A Multicentre, International Neoadjuvant (NA), Randomized, Double-blind Phase III Trial comparing FULVESTRANT to a combination of FULVESTRANT and PALBOCICLIB in patients with operable Luminal Breast Cancer (SAFIA Trial)
Presenter: Jean-Marc Nabholtz
Session: Poster Display session 2
Resources:
Abstract
5227 - Outcome of Non-metastatic Male Breast Cancer: 222 patients
Presenter: Ulku Yalcintas Arslan
Session: Poster Display session 2
Resources:
Abstract
5943 - Effects of delayed initiation of adjuvant trastuzumab for non-metastatic, Her2 positive breast cancer in a limited resources setting: ML25232 study final results
Presenter: Samir Beslija
Session: Poster Display session 2
Resources:
Abstract
1725 - Final results of scalp cooling for hair preservation: A single- institution prospective study.
Presenter: Dario Loparco
Session: Poster Display session 2
Resources:
Abstract
3713 - Adjuvant Systemic Therapy in Women with Early Breast Cancer and Intermediate Prosigna ROR Scores: Is Chemotherapy Use Declining? Evidence From a Large Practice
Presenter: Lowell Hart
Session: Poster Display session 2
Resources:
Abstract
818 - Management of early breast cancer in women over 90: A 10 year experience
Presenter: Emily Coffey
Session: Poster Display session 2
Resources:
Abstract
1141 - Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early- stage breast cancer.
Presenter: Daniel Reinhorn
Session: Poster Display session 2
Resources:
Abstract
2277 - Hepatitis B screening and incidence of flare among non-metastatic breast cancer patients treated with anthracyclines
Presenter: Zewen Zhang
Session: Poster Display session 2
Resources:
Abstract
2781 - Effect of denosumab on low bone mineral density in postmenopausal Japanese early breast cancer patients receiving aromatase nhibitors : 36-month results
Presenter: Koichi Sakaguchi
Session: Poster Display session 2
Resources:
Abstract